These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing ...

GoodRx says that with the support of a healthcare team, a clear transition plan, and a few cost-saving tools, you can make ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

Eli Lilly announced Thursday the successful completion of a phase 3 trial of Orforglipron – the first small-molecule GLP-1 that is administered as a once-daily oral pill. The ACHIEVE-1 trial ...

More than 65% of participants reached an A1C level below 6.5%. Orforglipron is the first small-molecule GLP-1 therapy to successfully complete a phase 3 trial. Eli Lilly plans to submit for ...

Over the past decade, the global pharmaceutical industry has witnessed a transformation in the treatment landscape for ...

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

Based on Caliway's preclinical data, co-administration of CBL-514 with GLP-1 significantly reduced post-discontinuation body weight regain and fat replenishment rate — suggesting that CBL-514 may help ...

GLP-1 drugs like Ozempic are associated with a higher risk of developing wet age-related macular degeneration in people with ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...